丽珠集团：公司创新药已形成清晰的上市规划

Core Viewpoint - Lijun Group has established a clear上市计划 for its innovative drugs, with a pipeline of products expected to launch annually starting this year, enhancing its sales growth and revenue structure [1] Group 1: Product Pipeline - The company plans to launch the innovative drug Aripiprazole microspheres in 2025, followed by products in the self-immune field for IL-17A/F psoriasis and ankylosing spondylitis, as well as P-CAB products in the digestive field within the next 2-3 years [1] - In three years, additional products such as NS-041 tablets for mental health, H001 capsules for cardiovascular health, flu vaccines, SG1001 for infections, and newly introduced oral GnRH antagonists are expected to be launched [1] Group 2: Business Stability and Growth - The company's main business remains stable, with multi-sector collaborative development, which will support sales growth as innovative drugs are launched [1] - The proportion of innovative drugs in the revenue structure is expected to increase over time, providing stronger support for overall sales growth [1] Group 3: Additional Product Developments - Besides the first and second category innovative drugs, the company is also developing high-barrier complex formulations and other products that synergize with Lijun, which are expected to launch in the coming years [1] - These include Semaglutide for diabetes and weight loss, recombinant FSH, Leuprolide microspheres (three-month sustained release), and long-acting products in the mental health field, further enhancing the company's growth momentum [1]